


Roldan, Lizette

From: LHusman@regionalhealth.com
Sent: Wednesday, March 02, 2011 12:22 PM
To: Roldan, Lizette
Cc: JMckee1@regionalhealth.com
Subject: RE: REQUEST FOR ADDITIONAL INFORMATION REGARDING CONTROL 573615

Docket No.: 030-03231
License No.: 40-00238-04
Control No.: 573615



Dear Lizette Roldan - Otero,

Please accept our responses to your e-mail below.

1. We confirm that we did and will use NUREG-1556, Volume 9, Revision 2 when developing procedures. The listed areas referring to NUREG-1556, Volume 9, Revision 1, dated October 2002 was incorrect.
2. Please remove Dr Ronald G. Drummond, Dr Richard J. Crilly and Mr. Darren Squire from our license.
3. Please remove the individual listed line items and increase our limit for "Any byproduct material permitted by 10 CFR 35.300" from 600 millicuries to 1460 millicuries."

Thank you
Lowell Husman, Nuclear Medicine Supervisor

Cc James McKee, RSO

From: Roldan, Lizette [<mailto:Lizette.Roldan@nrc.gov>]
Sent: Monday, February 28, 2011 10:04 AM
To: Husman, Lowell; McKee, James
Subject: REQUEST FOR ADDITIONAL INFORMATION REGARDING CONTROL 573615

Docket No.: 030-03231
License No.: 40-00238-04
Control No.: 573615

Dear Mr. Husman,

This is in reference to your application dated September 23, 2010 requesting a renewal for Nuclear Regulatory Commission License 40-00238-04. In order to continue our review, we need the following information:

1. In your request you commit to following procedures referenced in NUREG-1556 Volume 9, "Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Medical Uses Licenses" dated October 2002. There is a Revision 2 published in January 2008 for the aforementioned NUREG-1556 guidance. Please confirm that you will use the most recent NUREG-1556, Volume 9, Revision 2 when developing procedures.
2. Please note, there is one Authorized User and two Medical Physicist that are not mentioned in your renewal. Unless instructed otherwise, I will remove Dr Ronald G. Drummond, Dr Richard J. Crilly and Mr. Darren Squire from the license.

3. You have requested I-131, Samarium-153, Strontium-89 and Phosphate-32 (which should read Phosphorus-32) as separate line items. These isotopes are covered in the uses under 10 CFR 35.300. Therefore, they will not be written as a line item but consolidated into your request for "Any byproduct material permitted by 10 CFR 35.300". Therefore, you will see an increase on your limit for "Any byproduct material permitted by 10 CFR 35.300" from 600 millicuries to 1460 millicuries to account for the material requested as a line item.

We will continue our review upon receipt of this information. Please reply to my attention at the Region IV Office and refer to Mail Control No. 573615. Please respond to this e-mail by March 4, 2011. You may reply via PDF format, e-mail or by fax to 817-860-8263.

Sincerely,

Lizette Roldán-Otero, Ph.D.

Health Physicist

Nuclear Regulatory Commission

612 E. Lamar Blvd., Suite 400

Arlington, TX 76011

Office: 817-276-6596

Fax: 817-860-8263

Regional Health's mission is to provide and support health care excellence in partnership with the communities we serve.

Note: The information contained in this message, including any attachments, may be privileged, confidential, or protected from disclosure under state or federal laws. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the Sender immediately by a "reply to sender only" message and destroy all electronic or paper copies of the communication, including any attachments.